OR WAIT null SECS
July 01, 2021
Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.
The first participants, both previously vaccinated and unvaccinated, receive AstraZeneca’s new COVID-19 variant vaccine AZD2816.
WuXi STA’s Delaware campus will contain clinical and commercial manufacturing capabilities for small molecules and novel molecular modalities.
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sport medicine in the United States.
June 30, 2021
Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer.
Chalmers University researchers have developed a method to label and track mRNA molecules.
Amgen’s greenfield facility near Columbus, Ohio to assemble and package vials and syringes is expected to be operational by 2024.
CDMO Yposkesi will increase its current gene therapy vector capacity through French government’s “Plan de Relance” scheme.
Thermo Fisher Scientific has introduced its new Quick to Clinic solution, which is designed to accelerate biologic drug development from discovery to the IND phase in a shortened period.
CatSci has opened its new Dagenham, UK-based laboratory, which is dedicated to analytical excellence.